Trimarchi Thomas

BridgeBio CFO Thomas Trimarchi sells 13,651 shares for $888.4K via scheduled 10b5-1 plan on 2026-05-18

Thomas Trimarchi, President and CFO of BridgeBio Pharma, executed two separate sales totaling 13,651 shares for $888,419.17 on 2026-05-18, reducing his holdings by 3.7% to 359,194 shares post-transaction. The sales were executed through a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning the transactions were scheduled rather than discretionary. At BBIO specifically, Trimarchi's prior four measurable sales show mixed outcomes: two sales in February 2026 experienced 30-day declines of 6.2% and 7.0%, while two November 2025 sales saw 30-day gains of 11.8% and 10.7%. The company's fundamentals remain challenged: full-year net income was $-166.6M against quarterly revenue of $194.5M, though annual revenue growth reached +126.3%. Stock price is currently -22.3% from its 52-week high and down 14.0% over 30 days, reflecting the unprofitable operational status despite strong top-line expansion.

BridgeBio President/CFO Trimarchi sold 13,600 shares for $1.0M at $74.72 avg; retains 336.6K shares.

Thomas Trimarchi, President and CFO of BridgeBio Pharma, executed 2 separate sales totaling 13,600 shares for $1,016,147.12, reducing his holdings by 3.9% to 336,585 shares. The blended average price of $74.72 is above the current price of $73.93, meaning the transaction occurred near recent highs—approximately 7.5% below the 52-week high of $79.91. Notably, his prior 5 sales at BBIO showed a pattern of poor 90-day timing outcomes: in each case the stock subsequently rose (30-day average +6.2%, 90-day average +24.3%), resulting in a 0.00% well-timed rate, suggesting the insider's prior exit decisions preceded rally periods rather than declines. The company remains unprofitable with annual net income of $-184,937,000.00, though revenue has grown substantially at +2285.3% year-over-year, which may complicate interpretation of current valuation and near-term risk signals.

BridgeBio CFO Thomas Trimarchi sold 16,934 shares for $1,125,404.42 near 52-week highs; stock up 34.2% in 90 days despite unprofitable fundamentals.

Thomas Trimarchi, President and CFO of BridgeBio Pharma, executed 2 separate sales totaling 16,934 shares for $1,125,404.42 on 2025-11-17 at prices of $66.19 and $66.84 (blended average $66.46), selling near the 52-week high of $66.90. The company is currently unprofitable with net income of -$184,937,000.00 against quarterly revenue of $120,700,000.00, yet the stock is up 34.2% over the past 90 days and +19.4% over the past 30 days. Trimarchi retained 382,830 shares post-transaction, representing a -4.2% reduction in holdings. His prior 2 measurable same-ticker sales (August 2025) were poorly timed, with the stock subsequently rising 32.4% and 30.3% respectively at the 90-day mark, suggesting his timing decisions at this ticker have not successfully preceded declines.

BBIO CFO Thomas Trimarchi sold 42,237 shares at $49.48 on 2025-08-21; stock up 47.2% in 90 days amid unprofitable operations and 2285.3% revenue growth.

Thomas Trimarchi, President and CFO, sold 42,237 shares (representing a 9.1% reduction from his pre-transaction holdings of 463,318 shares) at $49.48, occurring as the stock has appreciated 47.2% over the prior 90 days and 6.3% over the past 30 days. The timing coincides with the stock trading near its 52-week high of $51.32, suggesting the sale occurred during a period of strong recent momentum. The company's fundamentals show exceptional headline growth—annual revenue grew 2285.3% year-over-year to $110,565,000—yet the business remains deeply unprofitable, with a net loss of $183,758,000 over the most recent full fiscal year, a typical pattern for early-stage biotech scaling revenue from near-zero bases. Trimarchi has two prior sales on record at this ticker (both on 2025-08-18), though outcomes on those are not yet measurable; his broader cross-ticker sell track record shows 2 prior opens-market sales, but neither was well-timed at the 90-day mark. The sale during a period of extraordinary price momentum and substantial unrealized gains in an unprofitable but rapidly growing biotech warrants attention to whether management views current valuations as unsustainable or whether this represents routine portfolio rebalancing by a long-term holder reducing an oversized position.

CFO Thomas Trimarchi sold 17,353 shares across 2 transactions for $871,722.42, reducing holdings by 3.6% while stock trades near 52-week highs

Thomas Trimarchi, President and CFO, executed 2 separate sales totaling 17,353 shares (17.4K shares) for $871,722.42 on 2025-08-18 at a blended average price of $50.23. The sales occurred as the stock trades at $48.91, near its 52-week high of $51.32 and up 48.9% over 90 days. Despite substantial recent gains, the company remains unprofitable with a net income of $-183,758,000.00 in its most recent full fiscal year, though quarterly revenue stands at $110,565,000.00 with extraordinary annual growth of +2285.3%. The reduction of 17,353 shares leaves Trimarchi with 463,318 shares post-transaction, representing a modest 3.6% reduction in his holdings. As a senior executive at an unprofitable biotech firm with volatile pricing dynamics, this filing warrants examination of whether additional context—such as a trading plan, vesting schedule, or other disclosed liquidity events—explains the transaction timing.